The investment company Nexttobe AB extends its MSEK 105 loan to Oasmia AB. The loan is due December 31, 2014 and the carried interest for the period 2014-01-01 to 2014-12-31 is set to 8.5 % Nexttobe is Oasmia’s second largest owner after Alseco International S.A. with 21.57 % of the shares in the company.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).